Citigroup.com Homepage
Insights

Future of Healthcare & Wellness: The Impact of GLP-1s on Sleep Apnea

Video  •  August 12, 2024
Share on LinkedIn
Share on Facebook
Share on Twitter
Copy Link
Print
Share with Email

Adam Spielman, Head of Health, Citi Global Insights with  Michael Farrell, CEO at ResMed and Carlos Nunez, CMO,  discuss the impact of GLP-1s on Sleep Apnea companies.

Key topics:

  • How do sleep apnea patients who use GLP-1s behave differently from non-users?
  • How does this affect companies providing solutions for obstructive sleep apnea
  • To what extent is ResMed changing its strategy because of GLP-1s?
  • If GLP-1s do reduce obesity long term, what impact would there be?
More about Insights

Related Stories

CITI GPS
Technology & Innovation

Future of Healthcare

The average global citizen born today will live almost 30 years longer than one of their forebears born in 1950, one of humanity’s most astonishing achievements.

Technology & Innovation

Future of Healthcare: The Oxford Prescription

Citi’s Adam Spielman, Head of Health, Citi Global Insights, with Rory Collins, Head of Nuffield Department of Population Health and BHF Professor of Medicine and Epidemiology and John Todd, Professor of Precision Medicine and Director of the Centre for Human Genetics (CHG) discuss how the faculty at the University of Oxford believe healthcare can be improved.

Technology & Innovation

Future of Health: The Impact of GLP-1s on Diabetes Care

Adam Spielman, Head of Health, Citi Global Insights with Jim Hollingshead, Chief Executive Officer, Insulet, discuss GLP-1s and their impact on Diabetes Care.

Sign up to receive the latest from Citi.